| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2014-11-17 | ALN-AC3 | hypertriglyceridemia |
preclinical | Alnylam Pharmaceuticals (USA - MA) | Cardiovascular diseases - Metabolic diseases |
| 2014-11-17 | ALN-ANG | genetic forms of mixed hyperlipidemia and severe hypertriglyceridemia |
Alnylam Pharmaceuticals (USA - MA) | Cardiovascular diseases - Metabolic diseases - Genetic diseases | |
| 2014-11-16 | secukinumab (AIN457) | psoriatic arthritis |
3 | Novartis (Switzerland) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2014-11-16 | MDCO-216 | coronary artery disease |
1 | The Medicines Company (USA - NJ) | Cardiovascular diseases |
| 2014-11-16 | lesinurad | gout |
3 | AstraZeneca (UK) | Inflammatory diseases |
| 2014-11-16 | Keytruda® (pembrolizumab) | ipilimumab-refractory advanced melanoma | 2 | Merck&Co (USA - NJ) | Cancer - Oncology |
| 2014-11-15 | RG-012 (single stranded, chemically modified oligonucleotide that binds to and inhibits the function of micro RNA-21) | Alport syndrome | preclinical | Sanofi (France) Regulus Therapeutics (USA - CA) | Rare diseases - Genetic diseases - Kidney diseases |
| 2014-11-15 | NovoTTF™-100A System in combination with standard-of-care temozolomide | glioblastoma |
3 | Novocure (UK) | Cancer - Oncology |
| 2014-11-15 | Opdivo® (nivolumab) | naïve BRAF wild-type advanced melanoma | 3 | BMS (USA - NY) | Cancer - Oncology |
| 2014-11-14 | rindopepimut | EGFRvIII-positive glioblastoma |
2 | Celldex Therapeutics (USA - NJ) | Cancer - Oncology - Rare diseases |
| 2014-11-13 | NER1006 | patients undergoing screening, surveillance or diagnostic colonoscopy recruitment of the first patient |
3 | Norgine Pharma (The Netherlands) | Gastrointestinal diseases - Digestive diseases |
| 2014-11-13 | DEZ-001 - TA-8995 | subjects with isolated, high Lipoprotein(a) or Lp(a) |
1b | Dezima Pharma (The Netherlands) | Cardiovascular diseases - Metabolic diseases |
| 2014-11-13 | VenaSeal™ closure system | chronic venous insufficiency |
Covidien (Ireland) | Cardiovascular diseases | |
| 2014-11-13 | sotatercept | patients with end-stage renal disease on hemodialysis |
2a | Acceleron Pharma (USA - MA) | Hematological diseases - Renal diseases |
| 2014-11-13 | riociguat | diffuse cutaneous systemic sclerosis |
2 | Bayer Healthcare (Germany) | Autoimmune diseases - Rare diseases |
| 2014-11-13 | MEDI2452 | reversion of the anticoagulant activity of Brilinta® |
preclinical | AstraZeneca (UK) | Cardiovascular diseases - Hematological diseases |
| 2014-11-13 | Halaven® (eribulin) | metastatic breast cancer |
3 | Eisai (Japan) | Cancer - Oncology |
| 2014-11-12 | ADS-5102 | levodopa-induced dyskinesia (LID) in patients with Parkinson\'s disease |
3 | Adamas Pharmaceuticals (USA - CA) | Neurodegenerative diseases - CNS diseases |
| 2014-11-12 | CSL112 | coronary heart disease |
2b | CSL (Australia) | Cardiovascular diseases |
| 2014-11-12 | eterplirsen | Duchenne Muscular Dystrophy | 2 | Sarepta Therapeutics (USA - MA) | Genetic diseases - Neuromuscular diseases - Rare diseases |
